Member Info for rhwillcoll

A rock solid wall of buys since 9.13, and still coming in. It looks to me as though we are about to go up strongly.

Just saying.

Since 9.13 there have been 23 buys and just two sells. Also, a 1 buy has just popped up.

Thank you for doing that. What great answers. Frankly, what a massive company in the making!

AND - we are here, all in, at the START!! This, I truly believe, is going to be the best investment possible.

Don't be tempted to sell any shares. You've already found the company that you were looking for!

I suspect that the MMs have little or no stock.

Remarkable that there aren't any late reported trades, for the first time in quite a long time. That's very encouraging.

I think that this will be reflected in the price from now on, imho. Well done fellow LTHs.

Very nice sudden price rise. Are we thinking that the MMs don't have any spare stock?

This is the company of the decade. Lovely just to have bought in and quietly wait.

CapAI is a strong buy today, according to investing.com

It is also a strong buy as far as I am concerned!

Thank you Icecool, I am looking at that. Much appreciated.

Hi Icecool, I've just send you a PM, if that is okay. You seem to be the most sensible person on this LSE board, by a long way!

Interesting: only one on offer @0.52, rest 0.55 etc. I think we'll go up again at 3 pm or so. All those buys behind the scenes, the late-reported trades every day. imho

7 Depth

0.52 1,000,000 PEEL 12:44

0.55 1,000,000 JBER 11:22

0.55 1,000,000 MREX 14:05

0.55 1,000,000 SCAP 11:33

0.55 1,000,000 STFL 11:33

0.58 1,000,000 WINS 14:05

0.59 1,000,000 SING 14:08

So far, 11 large late reported trades, including one for 50 million shares. So, an awful lot of further buying again today, as in previous days.

Just done some further research on previous FDA-approval of drugs they are working on. Most interesting and a cheaper and faster route to go down:

Prof Nag re fda approved drugs for aging

FDA-Approved Drugs Repurposed for Aging

Key FDA-Approved Drugs with Geroscience Potential

While no drug is FDA-approved specifically for "treating aging," several existing FDA-approved drugs are being repurposed and studied for their potential to delay age-related diseases and extend healthspan. According to recent expert reviews and prioritization frameworks, the leading candidates are:

SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin): Originally for diabetes, these drugs top the list for gerotherapeutic potential, with strong evidence for benefits across multiple age-related conditions.

Metformin: Widely used for type 2 diabetes, metformin is the subject of the large TAME trial, aiming to prove its ability to delay a cluster of age-related diseases.

Bisphosphonates: Used for osteoporosis, these drugs have emerging evidence for broader benefits in aging.

GLP-1 Receptor Agonists (e.g., semaglutide): Diabetes and weight loss drugs now being studied for their impact on aging and age-related diseases.

Other drugs with notable but slightly lower evidence include:

Acarbose

Rapamycin

Methylene blue

ACE inhibitors/ARBs

Beta blockers

Aspirin

Expert Involvement

Dr. Ronjon Nag is a prominent figure in the longevity and anti-aging field, but there is no evidence he has developed or directly led FDA approval of any anti-aging drug. Instead, the field is marked by collaborative efforts among geroscientists, with drugs like metformin and SGLT2 inhibitors being prioritized for large-scale clinical trials.

Summary Table: Top FDA-Approved Drugs Repurposed for Aging

Drug/Class Original Use Geroscience Evidence Score (out of 12)

SGLT2 inhibitors Diabetes 12

Metformin Diabetes 11

Bisphosphonates Osteoporosis 11

GLP-1 receptor agonists Diabetes/Obesity 10

Note: These drugs are not FDA-approved for aging itself, but are being studied and repurposed for this goal based on promising evidence.

Interesting re what Perplexity AI app says about Prof Nag developing an AI-guided “vaccine against aging,” aiming to extend human lifespan by 10–20 years using FDA-approved drugs selected by AI simulations. Most interesting if my understanding is that he is using already FDA- approved drugs. Much faster and easier re vaccine registration, if that is the case?

Prof Nag's plans for Capai

Professor Ronjon Nag’s Plans for CapAI

AI-Led Business Creation Model

Professor Ronjon Nag, a leading AI expert, recently joined CapAI as Executive Director and major shareholder.

CapAI is shifting to a new three-part business model: Identify, Incubate, and Invent, aiming to build a new generation of AI-powered companies.

The strategy focuses on the rise of "One-Person Unicorns"—startups built by individuals or small teams leveraging AI tools to scale rapidly and efficiently.

Strategic Partnerships

CapAI is in advanced talks to partner with R42, Nag’s Silicon Valley venture capital firm. This partnership would combine CapAI’s public market presence with R42’s technical and infrastructure support, targeting breakthroughs in sectors like media and healthcare.

Performance-Based Leadership

Nag’s remuneration at CapAI will be entirely performance-based, aligning his incentives with shareholder value and share price growth.

Focus on Longevity and AI in Medicine

Nag is also pursuing ambitious projects such as developing an AI-guided “vaccine against aging,” aiming to extend human lifespan by 10–20 years using FDA-approved drugs selected by AI simulations. This is part of his entry for the $101 million XPRIZE for longevity innovation.

Capital and Shareholder Value

CapAI has stated there are no current plans to raise new capital, aiming to avoid shareholder dilution unless absolutely necessary.

In summary, Professor Nag’s plans for CapAI centre on creating scalable AI-driven businesses, leveraging strategic partnerships, and pioneering innovations in AI and longevity, all while aligning leadership incentives with company performance and shareholder value.

I suspect that we will see a number of large after-hours trades again today, as in just about every other recent trading day!

Thank you Tonyship for the information you have posted re Prof Nag and Agemica. I use Perplexity as my AI app: it is great re providing up to date information, and is very research based.

Prof Nag has strongly indicated that his medical inventions will be included in the CapAI company. I guess it is too much too expect that Agemica will be included in total - that would be superb! He has talked about an anti-aging vaccine, which I think means anti-cancer and maybe several other vaccines. Whatever he brings will be transformative.

I too can see this become a billion-pound company relatively quickly. They are cherry-picking the most commercial parts of R42 in media and medicine as far as I can see. These are both mega-arenas in the AI field.

A brilliant company in the making, imho.

Prof Nag's Intentions for Media and Medicine at capAI: from my AI Machine. To me, this looks to become a massive company:

Strategic Focus

Prof Ronjon Nag, as Executive Director of capAI, is steering the company toward breakthrough opportunities in both media and medicine, leveraging AI to disrupt and reinvent these sectors.

capAI’s refined strategy, shaped by Nag’s leadership and a proposed alliance with his R42 Group, centers on identifying, incubating, and inventing AI-driven businesses specifically in media and healthcare.

Media

The intention is to harness AI for transformative innovation in the media sector, enabling the creation of new business models and tools, potentially allowing small teams or even individuals ("One-Person Unicorns") to build scalable, high-value media ventures.

Medicine

In medicine, Nag’s background as an Adjunct Professor in Genetics at Stanford and his experience with AI-biology intersections position capAI to pursue cutting-edge healthcare and biotech solutions, including longevity and diagnostics.

capAI-R42 Alliance

The proposed alliance with R42 Group combines capAI’s public market access with R42’s technical expertise and infrastructure, aiming to accelerate AI innovation in both media and medicine.

Summary Table

Sector Prof Nag’s Intentions at capAI

Media Disrupt and scale media businesses using advanced AI

Medicine Innovate in healthcare, longevity, and diagnostics

Prof Nag’s vision is to make capAI a leader in AI-powered transformation of both media and medicine, leveraging his expertise and the resources of R42 to drive rapid, high-impact innovation.

Keith and @AH5000 - much appreciate your hard work on this. Looks positive, and that is very satisfying.

Thank you both.

Small top up from myself also. A superb company to be invested in.

Just one left on 0.48p, rest on 0.50. Will go right up soon.

Day traders: best of luck getting back in, as you wait in long queue for your buy order to be processed.

A solid wall of buys are coming in. It is nice to see. This is a stock for LTHs, not chasing rainbows - which I am finding rather annoying.